Allo-iNKT cell therapy shows durable survival and immune restoration in PD-1–refractory tumours
Category: News
Lead ATAC candidate HDP-101 shows strong clinical activity and safety in phase 8 cohort
Real-time process mapping cuts manual workload and boosts frontline efficiency
CGT Catapult annual review shows sector’s impact on economy and patient access
Early treatment with vamorolone shows sustained efficacy and improved safety profile
Deal strengthens CNS portfolio and ensures continuity of access for MS patients
Three-year trial results reveal long-term improvements in pain and lesion resolution
New self-loading reagents offer unmatched flexibility for immunologists
First-in-class mast cell selective c-Kit inhibitor enters clinical testing in Germany
